Truist ups Amneal Pharmaceuticals price target, says pullback great entry point

TIPRANKS02-28

Truist analyst Les Sulewski raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares fo...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment